| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Samy A F Morad | Q84619532 |
| P2093 | author name string | Myles C Cabot | |
| P2860 | cites work | MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine | Q24317572 |
| Evolving concepts in cancer therapy through targeting sphingolipid metabolism | Q26863646 | ||
| Mechanism of fenretinide (4-HPR)-induced cell death | Q28210585 | ||
| Ceramide-mediated macroautophagy involves inhibition of protein kinase B and up-regulation of beclin 1 | Q28245694 | ||
| Synergistic cytotoxicity between tamoxifen and the plant toxin persin in human breast cancer cells is dependent on Bim expression and mediated by modulation of ceramide metabolism | Q28252027 | ||
| Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases | Q28265044 | ||
| Biochemical pharmacology of antiestrogen action | Q28267621 | ||
| Accumulation of glucosylceramides in multidrug-resistant cancer cells | Q28284394 | ||
| Ceramide synthase mediates daunorubicin-induced apoptosis: An alternative mechanism for generating death signals | Q28295232 | ||
| Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells | Q28301485 | ||
| High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine | Q28327767 | ||
| Modification of sphingolipid metabolism by tamoxifen and N-desmethyltamoxifen in acute myelogenous leukemia--Impact on enzyme activity and response to cytotoxics | Q30300370 | ||
| The apoptotic mechanism of action of the sphingosine kinase 1 selective inhibitor SKI-178 in human acute myeloid leukemia cell lines | Q30301001 | ||
| Recent advances in the development of P-gp inhibitors | Q30319108 | ||
| Targeting ceramide metabolism--a strategy for overcoming drug resistance | Q32133855 | ||
| Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma | Q33453845 | ||
| Chronic oral etoposide and tamoxifen in the treatment of far-advanced hepatocellular carcinoma | Q33495529 | ||
| Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group. | Q33496118 | ||
| Chemotherapy by slowing glucosphingolipid synthesis | Q33536408 | ||
| Glucosylceramide synthase, a factor in modulating drug resistance, is overexpressed in metastatic breast carcinoma | Q33683147 | ||
| beta-Sitosterol enhances tamoxifen effectiveness on breast cancer cells by affecting ceramide metabolism | Q40002839 | ||
| Modulation of ceramide metabolism in T-leukemia cell lines potentiates apoptosis induced by the cationic antimicrobial peptide bovine lactoferricin. | Q40010114 | ||
| Overexpression of glucosylceramide synthase in associated with multidrug resistance of leukemia cells | Q40091503 | ||
| New insights on the use of desipramine as an inhibitor for acid ceramidase | Q40244998 | ||
| Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1. | Q40352532 | ||
| Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. | Q40463031 | ||
| Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy. | Q40556362 | ||
| Role of multiple drug resistance protein 1 in neutral but not acidic glycosphingolipid biosynthesis | Q40609398 | ||
| A bioinformatic approach to the identification of candidate genes for the development of new cancer diagnostics | Q40658547 | ||
| Tumor gangliosides as targets for active specific immunotherapy of melanoma in man. | Q40670455 | ||
| P-glycoprotein modulates ceramide-mediated sensitivity of human breast cancer cells to tubulin-binding anticancer drugs. | Q40685415 | ||
| Tamoxifen: is it useful in the treatment of patients with metastatic melanoma? | Q40720852 | ||
| Tamoxifen: new membrane-mediated mechanisms of action and therapeutic advances | Q40752875 | ||
| Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study | Q40835485 | ||
| Tamoxifen as an antioxidant and cardioprotectant | Q41001391 | ||
| Structural and stereochemical studies of potent inhibitors of glucosylceramide synthase and tumor cell growth. | Q41364587 | ||
| Tamoxifen elicits rapid transmembrane lipid signal responses in human breast cancer cells | Q41386885 | ||
| Protein kinase C activity correlates with the growth rate of malignant gliomas: Part II. Effects of glioma mitogens and modulators of protein kinase C | Q41600478 | ||
| Multidrug resistance modulators and doxorubicin synergize to elevate ceramide levels and elicit apoptosis in drug-resistant cancer cells | Q41681702 | ||
| Interactions of tamoxifen, N-desmethyltamoxifen and 4-hydroxytamoxifen with P-glycoprotein and CYP3A. | Q42468095 | ||
| Tamoxifen induces selective membrane association of protein kinase C epsilon in MCF-7 human breast cancer cells | Q42540184 | ||
| Effect of tamoxifen on the pharmacokinetics of doxorubicin in patients with non-Hodgkin's lymphoma | Q42670133 | ||
| Expression of P-glycoprotein in HeLa cells confers resistance to ceramide cytotoxicity | Q42839236 | ||
| Tamoxifen and colchicine-modulated vinblastine followed by 5-fluorouracil in advanced renal cell carcinoma: a phase II study | Q43577978 | ||
| Acyl-CoA:cholesterol acyltransferase inhibition reduces atherosclerosis in apolipoprotein E-deficient mice | Q43624007 | ||
| Taxol-induced ceramide generation and apoptosis in human breast cancer cells | Q43629751 | ||
| Activity of high-dose toremifene plus cisplatin in platinum-treated non-small-cell lung cancer: a phase II California Cancer Consortium Trial | Q43697739 | ||
| High-dose tamoxifen added to concurrent biochemotherapy with decrescendo interleukin-2 in patients with metastatic melanoma | Q43707361 | ||
| Elevation of glucosylceramide in multidrug-resistant cancer cells and accumulation in cytoplasmic droplets | Q43773467 | ||
| Toremifene prevents prostate cancer in the transgenic adenocarcinoma of mouse prostate model | Q43913544 | ||
| Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979. | Q44231781 | ||
| Increasing intracellular ceramide: an approach that enhances the cytotoxic response in prostate cancer cells | Q44433066 | ||
| Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis | Q44445112 | ||
| Tamoxifen is a potent inhibitor of cholesterol esterification and prevents the formation of foam cells. | Q44655945 | ||
| Tamoxifen inhibits tumor cell invasion and metastasis in mouse melanoma through suppression of PKC/MEK/ERK and PKC/PI3K/Akt pathways. | Q46037572 | ||
| Distribution of tamoxifen and its metabolites in rat and human tissues during steady-state treatment. | Q48655283 | ||
| Targeting glucosylceramide synthase sensitizes imatinib-resistant chronic myeloid leukemia cells via endogenous ceramide accumulation | Q50436260 | ||
| ENZYMIC HYDROLYSIS AND SYNTHESIS OF CERAMIDES | Q51283755 | ||
| Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins. | Q52832264 | ||
| 1-phenyl-2-decanoylamino-3-morpholino-1-propanol chemosensitizes neuroblastoma cells for taxol and vincristine. | Q54057209 | ||
| A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer. | Q54077989 | ||
| Modification of ceramide metabolism increases cancer cell sensitivity to cytotoxics. | Q54084211 | ||
| Tamoxifen in the treatment of metastatic malignant melanoma: still a controversy? (Review). | Q33685200 | ||
| Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation: AC inhibition, a potential radiosensitizer | Q33713317 | ||
| Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group | Q33729158 | ||
| New selective estrogen and androgen receptor modulators | Q33814078 | ||
| Sphingosine kinase 1 in cancer | Q33853998 | ||
| Pharmacological strategies for overcoming multidrug resistance | Q33997660 | ||
| Identification of dihydroceramide desaturase as a direct in vitro target for fenretinide. | Q34182665 | ||
| Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents | Q34184687 | ||
| Inhibition of glucosylceramide synthase does not reverse drug resistance in cancer cells | Q34334511 | ||
| Multiple targeting by the antitumor drug tamoxifen: a structure-activity study. | Q34373392 | ||
| P-glycoprotein is implicated in the inhibition of ceramide-induced apoptosis in TF-1 acute myeloid leukemia cells by modulation of the glucosylceramide synthase pathway | Q34386376 | ||
| Gynomorphic mandible morphology in the dobsonfly, Corydalus cornutus | Q34392197 | ||
| Mechanisms of tamoxifen-induced apoptosis | Q34398439 | ||
| Toremifene--a promising therapy for the prevention of prostate cancer and complications of androgen deprivation therapy. | Q34497901 | ||
| Paclitaxel and tamoxifen: An active regimen for patients with metastatic melanoma | Q34506465 | ||
| Circulating sphingolipid biomarkers in models of type 1 diabetes | Q34560757 | ||
| Tamoxifen can reverse multidrug resistance of colorectal carcinoma in vivo | Q34605582 | ||
| Tamoxifen, raloxifene and the prevention of breast cancer | Q34605985 | ||
| The search for the ideal SERM. | Q34660744 | ||
| Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene | Q34896573 | ||
| Sphingolipids in neuroblastoma: their role in drug resistance mechanisms | Q34955797 | ||
| Targeting glucosylceramide synthase synergizes with C6-ceramide nanoliposomes to induce apoptosis in natural killer cell leukemia | Q34975327 | ||
| P-glycoprotein antagonists confer synergistic sensitivity to short-chain ceramide in human multidrug-resistant cancer cells. | Q35057879 | ||
| Advances in the science of estrogen receptor modulation | Q35060973 | ||
| Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions | Q35079156 | ||
| Acid ceramidase expression modulates the sensitivity of A375 melanoma cells to dacarbazine | Q35150141 | ||
| Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years | Q35173552 | ||
| Combinatorial therapies improve the therapeutic efficacy of nanoliposomal ceramide for pancreatic cancer | Q35556455 | ||
| The dynamics of drug resistance: a mathematical perspective | Q35946514 | ||
| Collateral sensitivity as a strategy against cancer multidrug resistance | Q35946556 | ||
| Drug resistance: still a daunting challenge to the successful treatment of AML. | Q35946969 | ||
| High-dose tamoxifen as an enhancer of etoposide cytotoxicity. Clinical effects and in vitro assessment in p-glycoprotein expressing cell lines | Q35994568 | ||
| Acid ceramidase-mediated production of sphingosine 1-phosphate promotes prostate cancer invasion through upregulation of cathepsin B | Q36063053 | ||
| Interaction of tamoxifen with the multidrug resistance P-glycoprotein. | Q36080370 | ||
| Ceramide toxicity and metabolism differ in wild-type and multidrug-resistant cancer cells. | Q54084215 | ||
| Synergistic antitumor effects of a combination of interferon and tamoxifen on estrogen receptor-positive and receptor-negative human tumor cell lines in vivo and in vitro. | Q54152249 | ||
| Phase I trial of high-dose tamoxifen as a modulator of drug resistance in combination with daunorubicin in patients with relapsed or refractory acute leukemia. | Q54161708 | ||
| The anticancer drug tamoxifen counteracts the pathology in a mouse model of duchenne muscular dystrophy. | Q54456171 | ||
| Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide. | Q54578505 | ||
| Multifactorial activities of nonsteroidal antiestrogens against leukemia | Q55037872 | ||
| Transport of sphingomyelin to the cell surface is inhibited by brefeldin A and in mitosis, where C6-NBD-sphingomyelin is translocated across the plasma membrane by a multidrug transporter activity | Q57075823 | ||
| Quantification of cholesteryl esters in human and rabbit atherosclerotic plaques by magic-angle spinning (13)C-NMR | Q57101925 | ||
| Effects of tamoxifen on serum lipid and apolipoprotein levels in postmenopausal patients with breast cancer | Q57337242 | ||
| Ceramide glycosylation potentiates cellular multidrug resistance | Q57373871 | ||
| Tamoxifen-induced cell death in malignant melanoma cells: possible involvement of the insulin-like growth factor-1 (IGF-1) pathway | Q58329828 | ||
| 4-HPR-mediated leukemia cell cytotoxicity is triggered by ceramide-induced mitochondrial oxidative stress and is regulated downstream by Bcl-2 | Q62969372 | ||
| Tamoxifen in Malignant Melanoma | Q66965989 | ||
| Growth effects of tamoxifen on Lovo colon carcinoma cells and cultured cells from normal colonic mucosa | Q67943160 | ||
| Influence of di- and tri-phenylethylene estrogen/antiestrogen structure on the mechanisms of protein kinase C inhibition and activation as revealed by a multivariate analysis | Q68028156 | ||
| Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma | Q70799346 | ||
| Comparative binding affinities of tamoxifen, 4-hydroxytamoxifen, and desmethyltamoxifen for estrogen receptors isolated from human breast carcinoma: correlation with blood levels in patients with metastatic breast cancer | Q71034377 | ||
| Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer | Q71093007 | ||
| Tamoxifen retards glycosphingolipid metabolism in human cancer cells | Q71618652 | ||
| Effect of oestrogen receptor status and time on the intra-tumoural accumulation of tamoxifen and N-desmethyltamoxifen following short-term therapy in human primary breast cancer | Q72032346 | ||
| A phase I trial of high-dose oral tamoxifen and CHOPE | Q72163473 | ||
| Tamoxifen activates cellular phospholipase C and D and elicits protein kinase C translocation | Q73115115 | ||
| Tamoxifen and gonadal steroids inhibit colon cancer growth in association with inhibition of thymidylate synthase, survivin and telomerase expression through estrogen receptor beta mediated system | Q73191476 | ||
| Treatment of advanced colorectal cancer with doxorubicin combined with two potential multidrug-resistance-reversing agents: high-dose oral tamoxifen and dexverapamil | Q73686816 | ||
| Glucosylceramide: a marker for multiple-drug resistant cancers | Q74500974 | ||
| The chemosensitizing activity of inhibitors of glucosylceramide synthase is mediated primarily through modulation of P-gp function | Q83035326 | ||
| Lactoferricin-induced apoptosis in estrogen-nonresponsive MDA-MB-435 breast cancer cells is enhanced by C6 ceramide or tamoxifen | Q83093942 | ||
| Resistance to the antiproliferative effect induced by a short-chain ceramide is associated with an increase of glucosylceramide synthase, P-glycoprotein, and multidrug-resistance gene-1 in cervical cancer cells | Q87548726 | ||
| Involvement of dihydroceramide desaturase in cell cycle progression in human neuroblastoma cells | Q36157119 | ||
| Ceramide--antiestrogen nanoliposomal combinations--novel impact of hormonal therapy in hormone-insensitive breast cancer | Q36392653 | ||
| Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. | Q36536479 | ||
| Ceramide and glucosylceramide upregulate expression of the multidrug resistance gene MDR1 in cancer cells | Q36600615 | ||
| Ceramides and other bioactive sphingolipid backbones in health and disease: lipidomic analysis, metabolism and roles in membrane structure, dynamics, signaling and autophagy | Q36628922 | ||
| Tamoxifen magnifies therapeutic impact of ceramide in human colorectal cancer cells independent of p53. | Q36704209 | ||
| The cardiovascular effects of selective estrogen receptor modulators. | Q36739272 | ||
| Acid ceramidase as a therapeutic target in metastatic prostate cancer. | Q36754783 | ||
| Targeting the sphingosine kinase/sphingosine 1-phosphate pathway in disease: review of sphingosine kinase inhibitors | Q36868420 | ||
| Acid ceramidase inhibition: a novel target for cancer therapy | Q36992435 | ||
| Targeting SphK1 as a new strategy against cancer | Q37172893 | ||
| Molecular targeting of acid ceramidase: implications to cancer therapy. | Q37239617 | ||
| Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine | Q37370640 | ||
| Is resistance useless? Multidrug resistance and collateral sensitivity | Q37414081 | ||
| Acid ceramidase upregulation in prostate cancer: role in tumor development and implications for therapy | Q37486242 | ||
| Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis | Q37621534 | ||
| Recent advances in the research of P-glycoprotein inhibitors | Q37681997 | ||
| Ceramidases in hematological malignancies: senseless or neglected target? | Q37894770 | ||
| Sphingolipid modulation: a strategy for cancer therapy | Q37921812 | ||
| Dihydroceramide desaturase and dihydrosphingolipids: debutant players in the sphingolipid arena | Q37971440 | ||
| Ceramide-orchestrated signalling in cancer cells. | Q38067062 | ||
| Diverse functions of ceramide in cancer cell death and proliferation | Q38071792 | ||
| Sphingosine kinase/sphingosine 1-phosphate signaling in cancer therapeutics and drug resistance | Q38096831 | ||
| Sphingolipids and response to chemotherapy. | Q38096835 | ||
| The role of sphingosine 1-phosphate in inflammation and cancer | Q38144498 | ||
| Importance of sphingosine kinase (SphK) as a target in developing cancer therapeutics and recent developments in the synthesis of novel SphK inhibitors | Q38182637 | ||
| Tamoxifen enhances erlotinib-induced cytotoxicity through down-regulating AKT-mediated thymidine phosphorylase expression in human non-small-cell lung cancer cells | Q39032303 | ||
| Novel off-target effect of tamoxifen--inhibition of acid ceramidase activity in cancer cells | Q39111178 | ||
| The roles of antiapoptotic sphingosine kinase-1 and glucosylceramide genes in drug induced cell death of MCF-7 breast cancer cells. | Q39396898 | ||
| Migration of MDA-MB-231 breast cancer cells depends on the availability of exogenous lipids and cholesterol esterification. | Q39509229 | ||
| Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)- retinamide in neuroblastoma cell lines | Q39511962 | ||
| Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism | Q39553593 | ||
| Acyl-coenzyme A: cholesterol acyltransferase inhibitor Avasimibe affect survival and proliferation of glioma tumor cell lines | Q39712980 | ||
| Metabolism of short-chain ceramide by human cancer cells--implications for therapeutic approaches. | Q39715843 | ||
| N-(4-Hydroxyphenyl)retinamide increases dihydroceramide and synergizes with dimethylsphingosine to enhance cancer cell killing | Q39940043 | ||
| Modulation of drug resistance in ovarian adenocarcinoma by enhancing intracellular ceramide using tamoxifen-loaded biodegradable polymeric nanoparticles | Q39981722 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | sphingolipids | Q410395 |
| tamoxifen | Q412178 | ||
| P304 | page(s) | 1134-1145 | |
| P577 | publication date | 2015-05-09 | |
| P1433 | published in | Biochimica et Biophysica Acta | Q864239 |
| P1476 | title | Tamoxifen regulation of sphingolipid metabolism--Therapeutic implications | |
| P478 | volume | 1851 |
| Q57107532 | Ceramide Metabolism Balance, a Multifaceted Factor in Critical Steps of Breast Cancer Development |
| Q30276873 | Ceramide-tamoxifen regimen targets bioenergetic elements in acute myelogenous leukemia |
| Q35804215 | Encyclopedia of bacterial gene circuits whose presence or absence correlate with pathogenicity--a large-scale system analysis of decoded bacterial genomes |
| Q48134167 | Expansion of Sphingosine Kinase and Sphingosine-1-Phosphate Receptor Function in Normal and Cancer Cells: From Membrane Restructuring to Mediation of Estrogen Signaling and Stem Cell Programming |
| Q56334125 | FTY720 enhances the anti-tumor activity of carboplatin and tamoxifen in a patient-derived xenograft model of ovarian cancer |
| Q36557315 | Hexokinase and phosphofructokinase activity and intracellular distribution correlate with aggressiveness and invasiveness of human breast carcinoma. |
| Q92331013 | Improvements in visual acuity and macular morphology following cessation of anti-estrogen drugs in a patient with anti-estrogen maculopathy resembling macular telangiectasia type 2: a pathogenic hypothesis |
| Q64973473 | Interdiction of Sphingolipid Metabolism Revisited: Focus on Prostate Cancer. |
| Q47673905 | Loss of acid ceramidase in myeloid cells suppresses intestinal neutrophil recruitment. |
| Q90642651 | Metabolic Plasticity in Chemotherapy Resistance |
| Q42120428 | MiR-124 acts as a tumor suppressor by inhibiting the expression of sphingosine kinase 1 and its downstream signaling in head and neck squamous cell carcinoma |
| Q40337387 | Mincle-Mediated Neutrophil Extracellular Trap Formation by Regulation of Autophagy |
| Q92189784 | Pivotal role of mitophagy in response of acute myelogenous leukemia to a ceramide-tamoxifen-containing drug regimen |
| Q90152296 | Resveratrol Modifies Lipid Composition of Two Cancer Cell Lines |
| Q30274798 | Role of P-glycoprotein inhibitors in ceramide-based therapeutics for treatment of cancer |
| Q92347503 | Sphingolipid metabolism and drug resistance in ovarian cancer |
| Q38944096 | Tamoxifen and amphetamine abuse: Are there therapeutic possibilities? |
| Q58567657 | Tamoxifen inhibits the biosynthesis of inositolphosphorylceramide in Leishmania |
| Q90065782 | Tamoxifen is a candidate first-in-class inhibitor of acid ceramidase that reduces amitotic division in polyploid giant cancer cells-Unrecognized players in tumorigenesis |
| Q90651738 | Targeting sphingolipid metabolism as an approach for combination therapies in haematological malignancies |
| Q48096434 | The UDP-glucose ceramide glycosyltransferase (UGCG) and the link to multidrug resistance protein 1 (MDR1). |
| Q30252512 | The emergence of acid ceramidase as a therapeutic target for acute myeloid leukemia |
| Q51146973 | UDP-glucose ceramide glucosyltransferase activates AKT, promoted proliferation, and doxorubicin resistance in breast cancer cells. |
Search more.